Medincell (MEDCL.PA) Stock Price

Medincell Price

Euronext·CLOSED
24.92EUR-0.44 (-1.75 %)
Market closed

Revenue has compounded at 11.4% per year over the past 10 years to 24.28 M EUR. Medincell's net margin stands at -128.9%, up from -606.5% several years earlier. Analysts set a median price target of 34.17 EUR, implying 37.1% above the current price. Of 17 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 58% above its 52-week low.

Medincell stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Medincell over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medincell stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medincell's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Medincell Stock Price History
DateMedincell Price
8/6/202624.92 EUR
8/5/202625.36 EUR
8/4/202624.68 EUR
7/31/202625.94 EUR
7/30/202626.10 EUR
7/29/202626.20 EUR
7/28/202625.60 EUR
7/27/202626.00 EUR
7/24/202626.00 EUR
7/23/202625.48 EUR
7/22/202625.40 EUR
7/21/202625.40 EUR
7/20/202625.10 EUR
7/17/202625.58 EUR
7/16/202625.50 EUR
7/15/202625.84 EUR
7/14/202626.42 EUR
7/13/202626.74 EUR
7/10/202627.10 EUR
7/9/202627.84 EUR
7/8/202628.56 EUR
7/7/202629.30 EUR
7/6/202628.48 EUR
7/3/202629.44 EUR
7/2/202629.40 EUR
7/1/202629.28 EUR
6/30/202628.64 EUR
6/29/202627.04 EUR
6/26/202625.98 EUR
6/25/202625.32 EUR
6/24/202625.02 EUR
6/23/202626.36 EUR
6/22/202625.06 EUR
6/19/202623.96 EUR
6/18/202625.22 EUR
6/17/202624.04 EUR
6/16/202628.18 EUR
6/15/202627.66 EUR
6/12/202627.28 EUR
6/11/202627.26 EUR
6/10/202626.72 EUR
6/9/202627.80 EUR
6/8/202627.72 EUR
6/5/202627.44 EUR
6/4/202626.32 EUR
6/3/202626.28 EUR
6/2/202627.18 EUR
6/1/202628.78 EUR
5/29/202629.14 EUR
5/28/202627.28 EUR
5/27/202626.78 EUR
5/26/202626.78 EUR
5/25/202626.92 EUR
5/22/202626.28 EUR
5/21/202626.38 EUR
5/20/202627.04 EUR
5/19/202626.02 EUR
5/18/202626.14 EUR
5/15/202627.38 EUR
5/14/202628.72 EUR
5/13/202628.08 EUR
5/12/202627.58 EUR
5/11/202627.06 EUR
5/8/202626.22 EUR
5/7/202626.34 EUR
5/6/202626.52 EUR
5/5/202625.08 EUR
5/4/202624.52 EUR
4/30/202624.68 EUR
4/29/202624.82 EUR
4/28/202622.86 EUR
4/27/202623.80 EUR
4/24/202623.16 EUR
4/23/202624.20 EUR
4/22/202624.08 EUR
4/21/202624.56 EUR
4/20/202623.90 EUR
4/17/202624.26 EUR
4/16/202624.10 EUR
4/15/202624.60 EUR
4/14/202625.12 EUR
4/13/202623.38 EUR
4/10/202623.22 EUR
4/9/202622.98 EUR
4/8/202622.00 EUR
4/7/202621.68 EUR
4/2/202623.10 EUR
4/1/202623.26 EUR
3/31/202622.54 EUR
3/30/202622.10 EUR
3/27/202622.20 EUR
3/26/202622.00 EUR
3/25/202621.82 EUR
3/24/202620.88 EUR
3/23/202621.50 EUR
3/20/202620.24 EUR
3/19/202620.46 EUR
3/18/202620.98 EUR
3/17/202620.98 EUR
3/16/202620.98 EUR
3/13/202620.34 EUR
3/12/202620.80 EUR
3/11/202622.06 EUR
3/10/202622.78 EUR
3/9/202621.82 EUR
3/6/202621.32 EUR
3/5/202622.64 EUR
3/4/202623.62 EUR
3/3/202622.38 EUR
3/2/202623.14 EUR
2/27/202623.04 EUR
2/26/202624.04 EUR
2/25/202624.94 EUR
2/24/202624.12 EUR
2/23/202624.68 EUR
2/20/202623.88 EUR
2/19/202624.04 EUR
2/18/202623.96 EUR
2/17/202624.54 EUR
2/16/202624.20 EUR
2/13/202625.02 EUR
2/12/202624.24 EUR
2/11/202624.12 EUR
2/10/202623.42 EUR
2/9/202624.32 EUR
2/6/202623.76 EUR
2/5/202623.32 EUR
2/4/202622.96 EUR
2/3/202623.10 EUR
2/2/202623.18 EUR
1/30/202622.56 EUR
1/29/202623.08 EUR
1/28/202624.02 EUR
1/27/202627.76 EUR
1/26/202626.38 EUR
1/23/202629.20 EUR
1/22/202628.74 EUR
1/21/202627.74 EUR
1/20/202627.06 EUR
1/19/202627.30 EUR
1/16/202628.22 EUR
1/15/202626.88 EUR
1/14/202627.58 EUR
1/13/202626.36 EUR
1/12/202626.42 EUR
1/9/202625.48 EUR
1/8/202625.66 EUR
1/7/202625.70 EUR
1/6/202624.46 EUR
1/5/202623.90 EUR
1/2/202624.72 EUR
12/31/202525.20 EUR
12/30/202524.66 EUR
12/29/202525.00 EUR
12/24/202525.02 EUR
12/23/202524.82 EUR
12/22/202525.10 EUR
12/19/202525.18 EUR
12/18/202525.64 EUR
12/17/202525.76 EUR
12/16/202527.00 EUR
12/15/202526.78 EUR
12/12/202527.56 EUR
12/11/202529.16 EUR
12/10/202527.50 EUR
12/9/202526.48 EUR
12/8/202526.68 EUR
12/5/202526.00 EUR
12/4/202525.90 EUR
12/3/202526.16 EUR
12/2/202525.90 EUR
12/1/202528.10 EUR
11/28/202528.16 EUR
11/27/202528.06 EUR
11/26/202529.12 EUR
11/25/202528.50 EUR
11/24/202528.12 EUR
11/21/202528.26 EUR
11/20/202528.68 EUR
11/19/202529.86 EUR
11/18/202530.36 EUR
11/17/202530.32 EUR
11/14/202530.44 EUR
11/13/202530.70 EUR
11/12/202530.72 EUR
11/11/202529.96 EUR
11/10/202529.48 EUR
11/7/202531.60 EUR
11/6/202531.64 EUR
11/5/202535.52 EUR
11/4/202537.62 EUR
11/3/202536.78 EUR
10/31/202538.46 EUR
10/30/202536.62 EUR
10/29/202536.42 EUR
10/28/202537.12 EUR
10/27/202536.32 EUR
10/24/202536.00 EUR
10/23/202534.88 EUR
10/22/202533.84 EUR
10/21/202535.50 EUR
10/20/202535.14 EUR
10/17/202533.90 EUR
10/16/202533.68 EUR
10/15/202532.82 EUR
10/14/202533.50 EUR
10/13/202533.22 EUR
10/10/202527.44 EUR
10/9/202528.64 EUR
10/8/202528.04 EUR
10/7/202527.16 EUR
10/6/202526.60 EUR
10/3/202526.58 EUR
10/2/202525.76 EUR
10/1/202524.98 EUR
9/30/202523.76 EUR
9/29/202523.20 EUR
9/26/202522.40 EUR
9/25/202522.26 EUR
9/24/202522.52 EUR
9/23/202522.04 EUR
9/22/202521.40 EUR
9/19/202521.24 EUR
9/18/202521.10 EUR
9/17/202520.64 EUR
9/16/202519.83 EUR
9/15/202520.16 EUR
9/12/202520.16 EUR
9/11/202519.45 EUR
9/10/202518.67 EUR
9/9/202518.60 EUR
9/8/202518.01 EUR
9/5/202516.94 EUR
9/4/202516.89 EUR
9/3/202517.10 EUR
9/2/202516.92 EUR
9/1/202517.13 EUR
8/29/202517.15 EUR
8/28/202517.32 EUR
8/27/202517.34 EUR
8/26/202517.35 EUR
8/25/202517.30 EUR
8/22/202517.91 EUR
8/21/202518.01 EUR
8/20/202517.77 EUR
8/19/202517.80 EUR
8/18/202517.49 EUR
8/15/202517.01 EUR
8/14/202516.45 EUR
8/13/202516.10 EUR
8/12/202515.87 EUR
8/11/202515.73 EUR
Access this data via the Eulerpool API
Get Free API Key

Medincell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
9.16 M EUR
-20.33 M EUR
-25.04 M EUR
Jan 1, 2025
25.54 M EUR
-13.19 M EUR
-18.44 M EUR
Jan 1, 2026
24.28 M EUR
-25.50 M EUR
-31.29 M EUR
Jan 1, 2027 (e)
47.41 M EUR
-41.44 M EUR
-1.18 M EUR
Jan 1, 2028 (e)
68.34 M EUR
-59.74 M EUR
17.49 M EUR
Jan 1, 2029 (e)
114.05 M EUR
-99.70 M EUR
49.82 M EUR
Jan 1, 2030 (e)
108.62 M EUR
-94.95 M EUR
51.37 M EUR
Jan 1, 2031 (e)
133.90 M EUR
-117.05 M EUR
78.83 M EUR

Medincell Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 12:25 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201620172018201920202021202220232024202520262027e2028e2029e2030e2031e
8.008.006.001.002.008.004.009.009.0025.0024.0047.0068.00114.00108.00133.00
––-25.00-83.33100.00300.00-50.00125.00–177.78-4.0095.8344.6867.65-5.2623.15
87.5087.50100.002,400.0050.0075.00100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00
7.007.006.0024.001.006.004.009.009.0025.0024.0047.0068.00114.00108.00133.00
–-3.00-7.00-17.00-19.00-16.00-22.00-28.00-20.00-13.00-25.00-41.00-59.00-99.00-94.00-117.00
–-37.50-116.67-1,700.00-950.00-200.00-550.00-311.11-222.22-52.00-104.17-87.23-86.76-86.84-87.04-87.97
–-3.00-9.00-19.00-23.00-19.00-24.00-32.00-25.00-18.00-31.00-1.0017.0049.0051.0078.00
––200.00111.1121.05-17.3926.3233.33-21.88-28.0072.22-96.77-1,800.00188.244.0852.94
14.4714.4520.0520.1021.0824.8025.2027.8729.1033.0835.9035.9035.9035.9035.9035.90
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Medincell generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medincell retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medincell's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Medincell has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medincell's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Medincell stock margins

The Medincell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medincell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medincell.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
100.00 %
-561.42 %
-606.50 %
Jan 1, 2023
100.00 %
-282.36 %
-321.90 %
Jan 1, 2024
100.00 %
-221.98 %
-273.34 %
Jan 1, 2025
100.00 %
-51.64 %
-72.19 %
Jan 1, 2026
100.00 %
-105.05 %
-128.88 %
Jan 1, 2027 (e)
100.00 %
-87.42 %
-2.48 %
Jan 1, 2028 (e)
100.00 %
-87.42 %
25.60 %
Jan 1, 2029 (e)
100.00 %
-87.42 %
43.68 %

Medincell Stock Revenue, EBIT, Earnings per Share

The Medincell earnings per share therefore indicates how much revenue Medincell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2022
0.16 EUR
-0.91 EUR
-0.98 EUR
Jan 1, 2023
0.36 EUR
-1.01 EUR
-1.15 EUR
Jan 1, 2024
0.31 EUR
-0.70 EUR
-0.86 EUR
Jan 1, 2025
0.77 EUR
-0.40 EUR
-0.56 EUR
Jan 1, 2026
0.68 EUR
-0.71 EUR
-0.87 EUR
Jan 1, 2027 (e)
1.60 EUR
-1.15 EUR
-0.04 EUR
Jan 1, 2028 (e)
2.31 EUR
-1.66 EUR
0.59 EUR
Jan 1, 2029 (e)
3.85 EUR
-2.78 EUR
1.68 EUR

Medincell business model & stock analysis

Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry.

Medincell SWOT Analysis

Strengths

Medincell SA has several key strengths which contribute to its success in the market. One of its main strengths is its innovative drug delivery technology, which allows for the controlled release of medications over extended periods of time. This technology provides significant advantages over traditional drug delivery methods, such as increased patient compliance and reduced side effects.

In addition, Medincell SA has a strong intellectual property portfolio, with numerous patents protecting its drug delivery technology. This provides the company with a competitive advantage and helps to ensure its long-term success in the market.

Weaknesses

Despite its strengths, Medincell SA also faces certain weaknesses that could potentially hinder its growth. One of the main weaknesses is the high cost of developing and commercializing its drug delivery technology. This can be a barrier to entry for some potential partners or investors.

Furthermore, Medincell SA's success heavily relies on the successful development and regulatory approval of its pipeline products. Any delay or failure in these processes can significantly impact the company's performance.

Opportunities

Medincell SA operates in a market with vast opportunities. The growing demand for improved drug delivery systems, especially in chronic disease management, presents a significant market opportunity for the company. Medincell SA's innovative technology positions it well to capture a substantial market share.

Additionally, strategic collaborations and partnerships with pharmaceutical companies could provide Medincell SA with access to broader distribution networks and resources, allowing for faster commercialization of its products.

Threats

Medincell SA faces several potential threats that could impact its business. One major threat is the presence of competitors in the drug delivery technology space. With the growing interest in this field, new entrants may emerge, posing a challenge to Medincell SA's market position.

Moreover, regulatory and compliance requirements in the healthcare industry can be complex and time-consuming. Failure to meet these requirements could lead to delays in product approvals and commercialization, reducing the company's competitive advantage.

Medincell Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Medincell historical P/E ratio, EBIT multiple, and P/S ratio

Medincell annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Medincell shares outstanding

The number of shares of Medincell was 33.08 M in 2025. This indicates how many shares Medincell is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
25.20 M Stocks
Jan 1, 2023
27.87 M Stocks
Jan 1, 2024
29.10 M Stocks
Jan 1, 2025
33.08 M Stocks
Jan 1, 2026
35.90 M Stocks
Jan 1, 2027 (e)
35.90 M Stocks
Jan 1, 2028 (e)
35.90 M Stocks
Jan 1, 2029 (e)
35.90 M Stocks

Current Medincell forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.03 %
Buy
94.12 % (16)
Hold
5.88 % (1)
Sell
0.00 % (0)
12M Price Target
34.17
Last Price
24.92
Currency
EUR
12M Return Potential
37.12 %
LTM Return
0 %

Medincell shareholder structure

% Name
5.46737%
Adage Capital Management, L.P.
Adage Capital Management, L.P.
4.59625%
Polar Capital LLP
Polar Capital LLP
3.00220%
Syquant Capital S.A.S
Syquant Capital S.A.S
1.99887%
Amundi Asset Management, SAS
Amundi Asset Management, SAS
1.29424%
BFT Investment Managers
BFT Investment Managers
1.23826%
Montpensier Arbevel, S.A.S.
Montpensier Arbevel, S.A.S.

Medincell Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.0%
Float Shares
-
Shares Outstanding
-

Medincell Executives and Management Board

16 members · avg. age 64 · 31 % women

CD

Mr. Christophe Douat

Chief Executive Officer, Executive Director · since 2014

489,873.00 EUR

Management

FP

Mr. Franck Pouzache

Chief People Officer

119,058.00 EUR
SP

Mr. Stephane Postic

Chief Financial Officer

–
PM

Mr. Philippe Moyen

Chief Operating Officer

–
JA

Ms. Julie Alimi

General Counsel, Chief Corporate Development Officer

–
SE

Mr. Sebastien Enault

Chief Business Officer

–
AL

Mr. Adolfo Lopez-Noriega

Head - Research and Development

–

Board of Directors

PG

Mr. Philippe Guy

Non-Executive Chairman of the Board · since 2010

70,056.00 EUR
TK

Ms. Tone Kvale (56)

Non-Executive Independent Director

47,000.00 EUR
VL

Ms. Virginie Lleu

Non-Executive Independent Director

47,000.00 EUR
EK

Ms. Elisabeth Kogan

Non-Executive Independent Vice Chairman of the Board

41,000.00 EUR
CK

Dr. Charles Kunsch

Independent Director

–
SM

Dr. Sharon Mates (72)

Independent Director

–

Frequently asked questions about Medincell

Medincell SA is a pharmaceutical company focusing on the development of long-acting injectable drug delivery systems. Their business model revolves around pioneering technology to create innovative products for controlled release of medicines. Medincell SA aims to enhance patient care by offering sustained-release formulations, providing a more convenient and effective treatment option. By leveraging their proprietary BEPO technology, Medincell SA aims to address therapeutic challenges and optimize drug delivery to improve clinical outcomes. With a dedication to research and development, Medincell SA aims to revolutionize the pharmaceutical industry and contribute to the advancement of patient healthcare.

Medincell SA is primarily active in the pharmaceutical industry.

The main competitors of Medincell SA in the market include pharmaceutical companies such as GlaxoSmithKline, Novartis, and Johnson & Johnson. These companies also specialize in developing and manufacturing innovative drug delivery technologies and products. Medincell SA faces competition in the market due to the constant need for advancements and solutions in the pharmaceutical industry.

Medincell SA is a pharmaceutical company specializing in controlled release drug delivery technologies. Founded in 2011, Medincell focuses on developing innovative therapeutic products to enhance treatment efficacy and patient adherence. The company is headquartered in Jacou, France, and operates with a team of experienced professionals dedicated to improving drug delivery systems. Medincell SA aims to revolutionize the pharmaceutical industry by offering sustained drug release solutions that provide targeted and continuous therapeutic effects. With a commitment to scientific excellence and advanced technologies, Medincell SA continues to make significant strides in the field of controlled release drug delivery.

Medincell SA has attained several notable milestones. Its most significant achievements include successful clinical trials for their long-acting injectable formulations, regulatory approvals for key products, and collaborations with reputed pharmaceutical companies. Notably, the company secured FDA approval for a long-acting antipsychotic treatment, MedinCell's Atrigenic, marking a significant milestone in the field of mental health therapeutics. Additionally, Medincell SA forged strategic partnerships with renowned pharmaceutical giants, enabling them to expand their reach and leverage their innovative drug delivery technologies. With these achievements, Medincell SA has established itself as a pioneering force in the pharmaceutical industry, driving advancements in long-acting drug formulations.

Medincell SA is primarily present in France and the United States.

Medincell SA is a renowned pharmaceutical company committed to innovation and research. With a strong focus on improving patients' lives, Medincell SA values integrity, excellence, and collaboration. The company's corporate philosophy revolves around delivering advanced drug delivery solutions and enhancing therapies. Medincell SA strives to develop partnerships and build a global network to accelerate the development and commercialization of its proprietary products. By integrating technology, science, and patient needs, Medincell SA aims to revolutionize drug delivery, offering sustainable and patient-centric solutions. Through its unwavering dedication to innovation and patient care, Medincell SA sets itself apart in the pharmaceutical industry.

Analysts currently set an average price target of 35.97 EUR for the Medincell stock (median: 34.17 EUR), implying +44.3 % versus the latest price. The consensus is based on 17 analyst ratings.

Medincell Analyst Price Targets 2026

17 analysts currently rate the Medincell stock: 16 recommend buying, 1 holding and 0 selling.

Medincell Analyst Price Targets 2026

The Medincell share (MEDCL.PA) is listed on 6 stock exchanges, including: Frankfurt (MEB.F), München (MEB.MU), London (0ACH.L), Paris (MEDCL.PA).

Medincell SA is a pharmaceutical company based in France that specializes in the development and marketing of long-acting drugs. The company is known for its groundbreaking technologies that allow for the release of medications into the body, resulting in a duration of up to three months. Medincell focuses on developing drugs for chronic diseases that require regular, long-term treatment. The company is composed of several business units that focus on different aspects of drug development and marketing. The research and development area is the core of Medincell, where the company develops its groundbreaking technologies and drug formulations. Medincell has a pipeline of projects aimed at developing long-acting drugs for use in chronic diseases. Another key area of Medincell is the manufacturing and marketing of its products. The company will not sell its products directly to end consumers, but rather to pharmaceutical companies, hospitals, or medical practices that will then prescribe them to patients. This allows Medincell to focus on developing high-quality, patient-oriented products without having to worry about direct marketing and distribution. Another important business area for Medincell is collaboration and partnerships with other pharmaceutical companies. Medincell has entered into a strategic partnership with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop a novel long-acting antipsychotic. In addition, the company has also entered into a collaboration with Pharmaserv Alliance to market its products in the United Arab Emirates and Saudi Arabia. Medincell is also advancing the development of its technology platform. The company is working on developing new release technologies for various types of drugs, including DNA-based therapeutics and cancer drugs. These technologies are intended to make medications even more effective and safer. In addition to the development and marketing of long-acting drugs, Medincell is also working on other solutions for the healthcare industry. These include innovative technologies for the administration of diabetes medications or the treatment of chronic pain. Overall, Medincell SA has an impressive and promising business strategy for the field of long-acting drug development. With innovative technologies, forward-thinking partnerships, and a clear focus on the needs of patients, the company expects to be successful in the future.

The revenue of Medincell is 24.28 M EUR. This figure is based on current financial data and reflects the company's business performance.

The profit of Medincell is -31.29 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medincell is currently -28.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medincell stock.

The price-to-sales ratio (P/S) of Medincell is currently 36.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medincell stock.

The Eulerpool Quality Score for Medincell is 4/10.

The ISIN of Medincell is FR0004065605. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medincell is A2N6VA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medincell is MEDCL.PA. The ticker symbol is used to trade Medincell shares on the stock exchange.

Medincell paid dividends every year for the past 0 years.

Medincell is assigned to the 'Health' sector.

The dividends of Medincell are distributed in EUR.

All fundamentals and in-depth analysis of Medincell

Our stock analysis for Medincell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medincell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Medincell Stock
Medincell Revenue→
Medincell Stock
Medincell Net Income→
Medincell Stock
Medincell P/E→
Medincell Stock
Medincell P/S→
Medincell Stock
Medincell EBIT→
Medincell Stock
Medincell Dividend→
Medincell Stock
Medincell Directors Dealings→
Medincell Stock
Medincell Stocks→
Medincell Stock
Medincell Market capitalization→
Medincell Stock
Medincell Debt→
Medincell Stock
Medincell Liabilities→
Medincell Stock
Medincell Equity→
Medincell Stock
Medincell AAQS→
Medincell Stock
Medincell Employees→
Medincell Stock
Medincell ROE→
Medincell Stock
Medincell ROA→
Medincell Stock
Medincell ROCE→
Medincell Stock
Medincell News→
Medincell Stock
Medincell Analyst Price Targets→

Health Stocks

Medinet CoMediNaviMediNet GroupMedikit CoMedinexMedikaloka Hermina Tbk PTMediniceMedigen Vaccine BiologicsMediosMedigen BiotechnologyMedipal HoldingsMedicureAll Stocks A–Z →